---
title: "TRVI.US (TRVI.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRVI.US/news.md"
symbol: "TRVI.US"
name: "TRVI.US"
parent: "https://longbridge.com/en/quote/TRVI.US.md"
datetime: "2026-05-20T11:53:08.911Z"
locales:
  - [en](https://longbridge.com/en/quote/TRVI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRVI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRVI.US/news.md)
---

# TRVI.US (TRVI.US) — Related News

### [Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030](https://longbridge.com/en/news/285805671.md)
*2026-05-09T09:05:20.000Z*
> Trevi Therapeutics (NASDAQ:TRVI) is advancing Haduvio, its extended-release formulation of nalbuphine, targeting chronic

### [Research Analysts Set Expectations for TRVI FY2030 Earnings](https://longbridge.com/en/news/285552816.md)
*2026-05-07T12:35:19.000Z*
> Equities researchers at HC Wainwright have lowered their FY2030 earnings estimates for Trevi Therapeutics (NASDAQ:TRVI) 

### [Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)](https://longbridge.com/en/news/285371618.md)
*2026-05-06T11:46:11.000Z*
> Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Trevi Therapeutics (TRVI) with a price target of $

### [Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline](https://longbridge.com/en/news/285313401.md)
*2026-05-06T04:55:18.000Z*
> Analyst Serge Belanger from Needham has reiterated a Buy rating on Trevi Therapeutics, lowering the price target to $23.

### [Trevi Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285302951.md)
*2026-05-06T03:15:19.000Z*
### [Trevi Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285259371.md)
*2026-05-05T20:17:09.000Z*
### [Why Trevi Therapeutics (TRVI) Is Down 7.3% After $150.8M Equity Raise And Share Authorization Boost](https://longbridge.com/en/news/284405340.md)
*2026-04-28T14:04:25.000Z*
> Trevi Therapeutics' stock fell 7.3% following a $150.8 million equity offering of 11.6 million shares at $13 each and a